118 related articles for article (PubMed ID: 8529770)
1. Changes in bone mineral content following hormone treatment for endometriosis.
Fukushima M
Int J Gynaecol Obstet; 1995 Sep; 50 Suppl 1():S17-22. PubMed ID: 8529770
[TBL] [Abstract][Full Text] [Related]
2. Hormone treatment related bone mineral content changes in Japanese women with endometriosis.
Fukushima M; Shindo M; Sato K
Asia Oceania J Obstet Gynaecol; 1993 Sep; 19(3):299-307. PubMed ID: 8250765
[TBL] [Abstract][Full Text] [Related]
3. Bone mass in endometriosis patients treated with GnRH agonist implant or danazol.
Dodin S; Lemay A; Maheux R; Dumont M; Turcot-Lemay L
Obstet Gynecol; 1991 Mar; 77(3):410-5. PubMed ID: 1825135
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of intranasal buserelin acetate in the treatment of endometriosis: a review of six clinical trials and comparison with danazol.
Trabant H; Widdra W; de Looze S
Prog Clin Biol Res; 1990; 323():357-82. PubMed ID: 2106146
[TBL] [Abstract][Full Text] [Related]
5. [Bone mineral content in premenopausal women treated with gonadotropin-releasing hormone analogue].
Masahashi T; Negoro Y; Asai M; Suzuki M; Noguchi M; Nakanishi M; Tomita A
Nihon Sanka Fujinka Gakkai Zasshi; 1992 May; 44(5):577-80. PubMed ID: 1619317
[TBL] [Abstract][Full Text] [Related]
6. Buserelin versus danazol in the treatment of endometriosis-associated infertility.
Fedele L; Bianchi S; Arcaini L; Vercellini P; Candiani GB
Am J Obstet Gynecol; 1989 Oct; 161(4):871-6. PubMed ID: 2529770
[TBL] [Abstract][Full Text] [Related]
7. Evidence of similar increases in bone turnover during nafarelin and danazol use in women with endometriosis.
Ylikorkala O; Nilsson CG; Hirvonen E; Viinikka L
Gynecol Endocrinol; 1990 Dec; 4(4):251-60. PubMed ID: 2150580
[TBL] [Abstract][Full Text] [Related]
8. Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women.
Matta WH; Shaw RW; Hesp R; Evans R
Clin Endocrinol (Oxf); 1988 Jul; 29(1):45-51. PubMed ID: 3150319
[TBL] [Abstract][Full Text] [Related]
9. The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis.
Whitehouse RW; Adams JE; Bancroft K; Vaughan-Williams CA; Elstein M
Clin Endocrinol (Oxf); 1990 Sep; 33(3):365-73. PubMed ID: 2147597
[TBL] [Abstract][Full Text] [Related]
10. Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study.
Fedele L; Marchini M; Bianchi S; Baglioni A; Zanotti F
Fertil Steril; 1993 Jun; 59(6):1191-5. PubMed ID: 8495764
[TBL] [Abstract][Full Text] [Related]
11. Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol.
Dawood MY; Lewis V; Ramos J
Fertil Steril; 1989 Jul; 52(1):21-6. PubMed ID: 2501109
[TBL] [Abstract][Full Text] [Related]
12. On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol.
Franssen AM; van der Heijden PF; Thomas CM; Doesburg WH; Willemsen WN; Rolland R
Fertil Steril; 1992 May; 57(5):974-9. PubMed ID: 1533376
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the skeletal effects of goserelin and danazol in premenopausal women with endometriosis.
Stevenson JC; Lees B; Gardner R; Shaw RW
Horm Res; 1989; 32 Suppl 1():161-3; discussion 164. PubMed ID: 2533148
[TBL] [Abstract][Full Text] [Related]
14. Hormonal therapies for endometriosis: implications for bone metabolism.
Dawood MY
Acta Obstet Gynecol Scand Suppl; 1994; 159():22-34. PubMed ID: 8209669
[TBL] [Abstract][Full Text] [Related]
15. Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin.
Dawood MY; Ramos J; Khan-Dawood FS
Fertil Steril; 1995 Jun; 63(6):1177-83. PubMed ID: 7750585
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of endometriosis. Evaluation of preoperative therapy with danazol, gestrinone and buserelin (nasal spray and implant)].
Nisolle M; Clerckx F; Casanas-Roux F; Gillerot S; Bourgonjon D; Donnez J
J Gynecol Obstet Biol Reprod (Paris); 1990; 19(6):759-63. PubMed ID: 2124231
[TBL] [Abstract][Full Text] [Related]
17. [Danazol and its effect on bone and lipid metabolism in patients with endometriosis].
Duque G; Bianchi M; Fernández C; Arteaga E
Rev Chil Obstet Ginecol; 1995; 60(1):34-7. PubMed ID: 8525034
[TBL] [Abstract][Full Text] [Related]
18. Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study.
Dmowski WP; Radwanska E; Binor Z; Tummon I; Pepping P
Fertil Steril; 1989 Mar; 51(3):395-400. PubMed ID: 2493400
[TBL] [Abstract][Full Text] [Related]
19. Low-dose GnRH agonist therapy for the management of endometriosis.
Uemura T; Shirasu K; Katagiri N; Asukai K; Suzuki T; Suzuki N; Osada H; Hiroshi M
J Obstet Gynaecol Res; 1999 Oct; 25(5):295-301. PubMed ID: 10533322
[TBL] [Abstract][Full Text] [Related]
20. Calcium metabolism in premenopausal women treated by a Gn-RH agonist for uterine myoma.
Ito M; Sakoda Y; Okamura H
Endocrinol Jpn; 1990 Dec; 37(6):907-13. PubMed ID: 1966283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
